Data updated: Mar 10, 2026
VESICARE LS
SOLIFENACIN SUCCINATE
Approved 2020-05-26
1
Indication
--
Phase 3 Trials
1
Priority Reviews
5
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2020-05-26
- Routes
- ORAL
- Dosage Forms
- SUSPENSION
VESICARE LS Approval History
Loading approval history...
What VESICARE LS Treats
1 FDA approvalsOriginally approved for its first indication in 2020 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VESICARE LS FDA Label Details
ProVESICARE LS Patents & Exclusivity
Latest Patent: May 2031
Patents (1 active)
US9918970
Expires May 18, 2031
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.